newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis

  • IGC Pharma's Phase 2 CALMA trial for IGC-AD1 in Alzheimer's agitation reached its target enrollment of 146 randomized patients.
  • The company will continue limited over-enrollment to account for attrition & support robust modified intent-to-treat, end-of-treatment, & exploratory analyses.
  • CEO Ram Mukunda stated that reaching 146 randomizations is a key operational milestone focused on generating a high-quality dataset for topline analysis.
  • Following over-enrollment completion & patient follow-up, IGC plans to proceed with database activities, site closeout, & subsequent topline analysis.
  • The CALMA trial is a randomized, double-blind, placebo-controlled Phase 2 study addressing agitation in Alzheimer's dementia.
  • IGC Pharma is a clinical-stage biotechnology firm using AI to develop treatments for Alzheimer's & metabolic disorders, with IGC-AD1 as its lead asset.
  • The company's pipeline includes TGR-63 targeting amyloid plaques & early-stage programs focused on neurodegeneration, tau proteins, & metabolic dysfunctions.